


**CLAIMS**

We claim:

1. A compound of formula (1) or a pharmaceutically acceptable salt thereof:



formula (1)

wherein:

 $Y^1$  and  $Y^2$  are independently O or S;z is  $NR^8$ , O or S;

- 10 n is 0 or 1;

W is  $NR^1$ ,  $CR^1R^2$  or a bond;

m is 0 or 1;

D is hydrogen,  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl or fluoro;X is  $-(CR^{12}R^{13})_t-Q-(CR^{14}R^{15})_u-$  where t and u are independently 0 or 1 and Q is O, S, SO or

- 15  $SO_2$ ;

B is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano,  $C_{1-4}$ alkyl (optionally substituted by  $R^9$  or  $C_{1-4}$ alkoxy or one or more halo),  $C_{2-4}$ alkenyl (optionally substituted by halo or  $R^9$ ),  $C_{2-4}$ alkynyl (optionally substituted by halo or  $R^9$ ),  $C_{3-6}$ cycloalkyl (optionally substituted by  $R^9$  or one or more halo),  $C_{5-6}$ cycloalkenyl (optionally substituted by halo or  $R^9$ ), aryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heteroaryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heterocyclyl (optionally substituted by  $C_{1-4}$ alkyl),  $-SR^{11}$ ,  $-SOR^{11}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $-NHCONR^9R^{10}$ ,  $-OR^9$ ,  $-NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; or B is  $C_{2-4}$ alkenyl or  $C_{2-4}$ alkynyl, each being optionally substituted by a group selected from  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more halo,

- 25

nitro, cyano, trifluoromethyl, trifluoromethoxy,  $-\text{CONHR}^9$ ,  $-\text{CONR}^9\text{R}^{10}$ ,  $-\text{SO}_2\text{R}^{11}$ ,  $-\text{SO}_2\text{NR}^9\text{R}^{10}$ ,  $-\text{NR}^9\text{SO}_2\text{R}^{11}$ ,  $\text{C}_{1-4}\text{alkyl}$  or  $\text{C}_{1-4}\text{alkoxy}$ ; with the provisos that:

when  $n$  is 1 and  $W$  is  $\text{NR}^1$ ,  $\text{CR}^1\text{R}^2$  or a bond; or when  $n$  is 0 and  $W$  is  $\text{CR}^1\text{R}^2$ ; then  $B$  is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally

5 substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano,  $\text{C}_{1-4}\text{alkyl}$  (optionally substituted by  $\text{R}^9$  or  $\text{C}_{1-4}\text{alkoxy}$  or one or more halo),  $\text{C}_{2-4}\text{alkenyl}$  (optionally substituted by halo or  $\text{R}^9$ ),  $\text{C}_{2-4}\text{alkynyl}$  (optionally substituted by halo or  $\text{R}^9$ ),  $\text{C}_{3-6}\text{cycloalkyl}$  (optionally substituted by  $\text{R}^9$  or one or more halo),  $\text{C}_{5-6}\text{cycloalkenyl}$  (optionally substituted by halo or  $\text{R}^9$ ), aryl (optionally substituted by halo or

10  $\text{C}_{1-4}\text{alkyl}$ ), heteroaryl (optionally substituted by halo or  $\text{C}_{1-4}\text{alkyl}$ ), heterocyclyl (optionally substituted by  $\text{C}_{1-4}\text{alkyl}$ ),  $-\text{SR}^{11}$ ,  $-\text{SOR}^{11}$ ,  $-\text{SO}_2\text{R}^{11}$ ,  $-\text{SO}_2\text{NR}^9\text{R}^{10}$ ,  $-\text{NR}^9\text{SO}_2\text{R}^{11}$ ,  $-\text{NHCONR}^9\text{R}^{10}$ ,  $-\text{OR}^9$ ,  $-\text{NR}^9\text{R}^{10}$ ,  $-\text{CONR}^9\text{R}^{10}$  and  $-\text{NR}^9\text{COR}^{10}$ ; or  $B$  is  $\text{C}_{2-4}\text{alkenyl}$  or  $\text{C}_{2-4}\text{alkynyl}$ , each being optionally substituted by a group selected from  $\text{C}_{1-4}\text{alkyl}$ ,  $\text{C}_{3-6}\text{cycloalkyl}$ , aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more halo,

15 nitro, cyano, trifluoromethyl, trifluoromethoxy,  $-\text{CONHR}^9$ ,  $-\text{CONR}^9\text{R}^{10}$ ,  $-\text{SO}_2\text{R}^{11}$ ,  $-\text{SO}_2\text{NR}^9\text{R}^{10}$ ,  $-\text{NR}^9\text{SO}_2\text{R}^{11}$ ,  $\text{C}_{1-4}\text{alkyl}$  or  $\text{C}_{1-4}\text{alkoxy}$ ; and

when  $n$  is 0 and  $W$  is  $\text{NR}^1$  or a bond; then  $B$  is a group selected from bicyclic aryl, bicyclic heteroaryl and bicyclic heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo,

20 cyano,  $\text{C}_{1-4}\text{alkyl}$  (optionally substituted by  $\text{R}^9$  or  $\text{C}_{1-4}\text{alkoxy}$  or one or more halo),  $\text{C}_{2-4}\text{alkenyl}$  (optionally substituted by halo or  $\text{R}^9$ ),  $\text{C}_{2-4}\text{alkynyl}$  (optionally substituted by halo or  $\text{R}^9$ ),  $\text{C}_{3-6}\text{cycloalkyl}$  (optionally substituted by  $\text{R}^9$  or one or more halo),  $\text{C}_{5-6}\text{cycloalkenyl}$  (optionally substituted by halo or  $\text{R}^9$ ), aryl (optionally substituted by halo or  $\text{C}_{1-4}\text{alkyl}$ ), heteroaryl (optionally substituted by halo or  $\text{C}_{1-4}\text{alkyl}$ ), heterocyclyl (optionally substituted by  $\text{C}_{1-4}\text{alkyl}$ ),

25  $-\text{SR}^{11}$ ,  $-\text{SOR}^{11}$ ,  $-\text{SO}_2\text{R}^{11}$ ,  $-\text{SO}_2\text{NR}^9\text{R}^{10}$ ,  $-\text{NR}^9\text{SO}_2\text{R}^{11}$ ,  $-\text{NHCONR}^9\text{R}^{10}$ ,  $-\text{OR}^9$ ,  $-\text{NR}^9\text{R}^{10}$ ,  $-\text{CONR}^9\text{R}^{10}$  and  $-\text{NR}^9\text{COR}^{10}$ ; or  $B$  is  $\text{C}_{2-4}\text{alkenyl}$  or  $\text{C}_{2-4}\text{alkynyl}$ , each being optionally

substituted by a group selected from  $\text{C}_{1-4}\text{alkyl}$ ,  $\text{C}_{3-6}\text{cycloalkyl}$ , aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy,  $-\text{CONHR}^9$ ,  $-\text{CONR}^9\text{R}^{10}$ ,  $-\text{SO}_2\text{R}^{11}$ ,  $-\text{SO}_2\text{NR}^9\text{R}^{10}$ ,  $-\text{NR}^9\text{SO}_2\text{R}^{11}$ ,  $\text{C}_{1-4}\text{alkyl}$  or

30  $\text{C}_{1-4}\text{alkoxy}$ ;

$R^1$  and  $R^2$  are independently hydrogen or a group selected from  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{3-6}$ cycloalkyl and  $C_{5-6}$ cycloalkenyl which group may be optionally substituted by halo, cyano, hydroxy or  $C_{1-4}$ alkoxy;

- $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are independently hydrogen or a group selected from  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{3-6}$ cycloalkyl,  $C_{5-6}$ cycloalkenyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethyloxy,  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkynyl,  $C_{3-6}$ cycloalkyl (optionally substituted by one or more  $R^{17}$ ), aryl (optionally substituted by one or more  $R^{17}$ ), heteroaryl (optionally substituted by one or more  $R^{17}$ ), heterocyclyl,  $-OR^{18}$ ,  $-SR^{19}$ ,  $-SOR^{19}$ ,  $-SO_2R^{19}$ ,  $-COR^{19}$ ,  $-CO_2R^{18}$ ,  $-CONR^{18}R^{20}$ ,  $-NR^{16}COR^{18}$ ,  $-SO_2NR^{18}R^{20}$  and  $-NR^{16}SO_2R^{19}$ ; or  $R^1$  and  $R^3$  together with the nitrogen or carbon atoms and carbon atom to which they are respectively attached form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon by  $C_{1-4}$ alkyl, fluoro or  $C_{1-4}$ alkoxy and/or on nitrogen by  $-COC_{1-3}$ alkyl,  $-SO_2C_{1-3}$ alkyl or  $C_{1-4}$ alkyl;

- or  $R^3$  and  $R^4$  together form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon by  $C_{1-4}$ alkyl, fluoro or  $C_{1-4}$ alkoxy and/or on nitrogen by  $-COC_{1-3}$ alkyl,  $-SO_2C_{1-3}$ alkyl or  $C_{1-4}$ alkyl;
- or  $R^5$  and  $R^6$  together form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon by  $C_{1-4}$ alkyl, fluoro or  $C_{1-4}$ alkoxy and/or on nitrogen by  $-COC_{1-3}$ alkyl,  $-SO_2C_{1-3}$ alkyl or  $C_{1-4}$ alkyl;

- $R^7$  is hydrogen or a group selected from  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl, heteroalkyl,  $C_{3-7}$ cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by halo,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $C_{3-7}$ cycloalkyl, heterocyclyl, aryl, heteroaryl or heteroalkyl; and wherein the group from which  $R^7$  may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano,  $C_{1-4}$ alkyl, nitro, halo $C_{1-4}$ alkyl, heteroalkyl, aryl, heteroaryl, hydroxy $C_{1-4}$ alkyl,  $C_{3-7}$ cycloalkyl, heterocyclyl,  $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, halo $C_{1-4}$ alkoxy $C_{1-4}$ alkyl,  $-COC_{1-4}$ alkyl,  $-OR^{21}$ ,  $-CO_2R^{21}$ ,  $-SOR^{25}$ ,  $-SO_2R^{25}$ ,  $-NR^{21}COR^{22}$ ,  $-CONR^{21}R^{22}$  and  $-NHCONR^{21}R^{22}$ ;

-61-

or  $R^3$  and  $R^7$  together with the carbon atoms to which they are each attached and  $(CR^5R^6)_n$  form a saturated 5- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon by  $C_{1-4}$ alkyl, fluoro or  $C_{1-4}$ alkoxy and/or on nitrogen by  $-COC_{1-3}$ alkyl,  $-SO_2C_{1-3}$ alkyl or  $C_{1-4}$ alkyl;

5  $R^8$  is selected from hydrogen,  $C_{1-6}$ alkyl and halo $C_{1-6}$ alkyl;

$R^9$  and  $R^{10}$  are independently hydrogen,  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl;

or  $R^9$  and  $R^{10}$  together with the nitrogen to which they are attached form a heterocyclic 4 to 7-membered ring.

$R^{11}$  is  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl;

10  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  are independently selected from hydrogen,  $C_{1-6}$ alkyl and  $C_{3-6}$ cycloalkyl;

$R^{16}$  is hydrogen or  $C_{1-6}$ alkyl;

$R^{17}$  is selected from halo,  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl and  $C_{1-6}$ alkoxy;

$R^{18}$  is hydrogen or a group selected from  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl,  $C_{5-7}$ cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, aryl $C_{1-4}$ alkyl and heteroaryl $C_{1-4}$ alkyl which group is optionally

15 substituted by one or more halo;

$R^{19}$  and  $R^{25}$  are independently a group selected from  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl,  $C_5$

$7$ cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, aryl $C_{1-4}$ alkyl and heteroaryl $C_{1-4}$ alkyl which group is optionally substituted by one or more halo;

$R^{20}$  is hydrogen,  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl;


20 or  $R^{18}$  and  $R^{20}$  together with the nitrogen to which they are attached form a heterocyclic 4- to 7- membered ring;

$R^{21}$  and  $R^{22}$  are independently hydrogen,  $C_{1-4}$ alkyl, halo $C_{1-4}$ alkyl, aryl and aryl $C_{1-4}$ alkyl;

or  $R^{21}$  and  $R^{22}$  together with the nitrogen to which they are attached form a heterocyclic 5- to 6- membered ring.

25

2. A compound of formula (1) or a pharmaceutically acceptable salt thereof:



wherein:

$Y^1$  and  $Y^2$  are independently O or S;

z is  $NR^8$ , O or S;

n is 0;

5 W is  $NR^1$ ;

m is 0 or 1;

D is hydrogen,  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl or fluoro;

X is  $-(CR^{12}R^{13})_t-Q-(CR^{14}R^{15})_u-$  where t and u are independently 0 or 1 and Q is O, S, SO or  $SO_2$ ;

10 B is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano,  $C_{1-4}$ alkyl (optionally substituted by  $R^9$  or  $C_{1-4}$ alkoxy or one or more halo),  $C_{2-4}$ alkenyl (optionally substituted by halo or  $R^9$ ),  $C_{2-4}$ alkynyl (optionally substituted by halo or  $R^9$ ),  $C_{3-6}$ cycloalkyl (optionally substituted by  $R^9$  or one or more halo),

15  $C_{5-6}$ cycloalkenyl (optionally substituted by halo or  $R^9$ ), aryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heteroaryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heterocyclyl (optionally substituted by  $C_{1-4}$ alkyl),  $-SR^{11}$ ,  $-SOR^{11}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $-NHCONR^9R^{10}$ ,  $-OR^9$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ;

$R^1$  is hydrogen or a group selected from  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{3-6}$ cycloalkyl and

20  $C_{5-6}$ cycloalkenyl which group may be optionally substituted by halo, cyano, hydroxy or  $C_{1-4}$ alkoxy;

$R^3$  and  $R^4$  are independently hydrogen or a group selected from  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkynyl,  $C_{3-5}$ cycloalkyl, pentenyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano,

25 trifluoromethyl, trifluoromethoxy,  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkynyl,  $C_{3-6}$ cycloalkyl (optionally substituted by one or more  $R^{17}$ ), aryl (optionally substituted by one or more  $R^{17}$ ), heteroaryl (optionally substituted by one or more  $R^{17}$ ), heterocyclyl,  $-OR^{18}$ ,  $-SR^{19}$ ,  $-SOR^{19}$ ,  $-SO_2R^{19}$ ,  $-CONR^{18}R^{20}$  and  $-NR^{16}COR^{18}$ ;

or  $R^1$  and  $R^3$  together with the nitrogen and carbon atoms to which they are respectively

30 attached form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon

by C<sub>1-4</sub>alkyl, fluoro or C<sub>1-4</sub>alkoxy and/or on nitrogen by -COC<sub>1-3</sub>alkyl, -SO<sub>2</sub>C<sub>1-3</sub>alkyl or C<sub>1-4</sub>alkyl;

or R<sup>3</sup> and R<sup>4</sup> together form a carbocyclic or saturated heterocyclic 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and SO<sub>2</sub> where

5 the ring is optionally substituted on carbon by C<sub>1-4</sub>alkyl, fluoro or C<sub>1-4</sub>alkoxy and/or on nitrogen by -COC<sub>1-3</sub>alkyl, -SO<sub>2</sub>C<sub>1-3</sub>alkyl or C<sub>1-4</sub>alkyl;

R<sup>7</sup> is hydrogen or a group selected from C<sub>1-4</sub>alkyl, heteroalkyl, C<sub>3-5</sub>cycloalkyl, aryl, heteroaryl or heterocyclyl which group is optionally substituted by halo, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>3-5</sub>cycloalkyl, heterocyclyl, aryl, heteroaryl or heteroalkyl; and wherein the group from which R<sup>7</sup>

10 may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano, C<sub>1-4</sub>alkyl, nitro, haloC<sub>1-4</sub>alkyl, heteroalkyl, aryl, heteroaryl, hydroxyC<sub>1-4</sub>alkyl, C<sub>3-5</sub>cycloalkyl, heterocyclyl, C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl, -COC<sub>1-4</sub>alkyl, -OR<sup>21</sup>, -CO<sub>2</sub>R<sup>21</sup>, -SR<sup>25</sup>, -SOR<sup>25</sup>, -SO<sub>2</sub>R<sup>25</sup>, -CONR<sup>21</sup>R<sup>22</sup> and -NHCONR<sup>21</sup>R<sup>22</sup>;

15 or R<sup>3</sup> and R<sup>7</sup> together with the carbon atoms to which they are each attached and (CR<sup>5</sup>R<sup>6</sup>)<sub>n</sub> form a saturated carbocyclic or heterocyclic 5- or 6-membered ring;

R<sup>8</sup> is selected from hydrogen, C<sub>1-4</sub>alkyl and haloC<sub>1-4</sub>alkyl;

R<sup>9</sup> and R<sup>10</sup> are independently hydrogen, C<sub>1-6</sub>alkyl or C<sub>3-6</sub>cycloalkyl;

or R<sup>9</sup> and R<sup>10</sup> together with the nitrogen to which they are attached form a heterocyclic 4 to 6-  
20 membered ring.

R<sup>11</sup> is C<sub>1-4</sub>alkyl or C<sub>3-5</sub>cycloalkyl;

R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup> and R<sup>15</sup> are independently selected from hydrogen, C<sub>1-4</sub>alkyl and C<sub>3-4</sub>cycloalkyl;

R<sup>16</sup> is hydrogen or C<sub>1-4</sub>alkyl;

R<sup>17</sup> is selected from halo, C<sub>1-4</sub>alkyl, C<sub>3-5</sub>cycloalkyl and C<sub>1-4</sub>alkoxy;

25 R<sup>18</sup> is hydrogen or a group selected from C<sub>1-4</sub>alkyl, C<sub>3-5</sub>cycloalkyl, C<sub>5-6</sub>cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC<sub>1-4</sub>alkyl and heteroarylC<sub>1-4</sub>alkyl which group is optionally substituted by one or more halo;

R<sup>19</sup> and R<sup>25</sup> are independently a group selected from C<sub>1-4</sub>alkyl, C<sub>3-5</sub>cycloalkyl, C<sub>5-6</sub>cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC<sub>1-4</sub>alkyl and heteroarylC<sub>1-4</sub>alkyl

30 which group is optionally substituted by one or more halo;

R<sup>20</sup> is hydrogen, C<sub>1-4</sub>alkyl or C<sub>3-5</sub>cycloalkyl;

or  $R^{18}$  and  $R^{20}$  together with the nitrogen to which they are attached form a heterocyclic 4- to 6- membered ring;

$R^{21}$  and  $R^{22}$  are independently hydrogen,  $C_{1-4}$ alkyl, halo $C_{1-4}$ alkyl, aryl and aryl $C_{1-4}$ alkyl;

or  $R^{21}$  and  $R^{22}$  together with the nitrogen to which they are attached form a heterocyclic 5- to 6- membered ring.


3. A compound according to claim 1 wherein B is phenyl, naphthyl, pyridyl, quinoliny, isoquinoliny, thienopyridyl, naphthyridinyl, 2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, thienopyrimidinyl, pyridoimidazolyl, benzimidazolyl, benzofuranyl, benzothienyl, indolyl, benzothiazolyl, benzotriazolyl, benzisoxazolyl, benzisothiazolyl, indazolyl, indoliziny, isobenzofuranyl, quinazolinyl, imidazopyridinyl, pyrazolopyridinyl, indoliny, tetrahydroquinoliny, tetrahydroisoquinoliny or isoindoliny, where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo,  $C_{1-4}$ alkyl (optionally substituted by one or more halo),  $C_{2-4}$ alkynyl, heteroaryl,  $-OR^9$ , cyano,  $-NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; or B is vinyl or ethynyl optionally substituted by  $C_{1-4}$ alkyl.

4. A compound according to claim 1 or 2 wherein B is a group selected from bicyclic aryl, bicyclic heteroaryl and bicyclic heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo,  $C_{1-4}$ alkyl (optionally substituted by one or more halo),  $C_{2-4}$ alkynyl, heteroaryl,  $-OR^9$ , cyano,  $-NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; or B is  $C_{2-4}$ alkenyl or  $C_{2-4}$ alkynyl optionally substituted by  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl or heterocyclyl.

5. A compound according to claim 1 or 2 wherein B is 2-methylquinolin-4-yl.

6. A compound according to any one of the preceding claims wherein  $R^7$  is hydrogen or a group selected from  $C_{1-4}$ alkyl, aryl $C_{1-4}$ alkyl, heteroaryl $C_{1-4}$ alkyl, heterocyclyl $C_{1-4}$ alkyl, aryl, heteroaryl, heterocyclyl and  $C_{3-5}$ cycloalkyl which group is optionally substituted by cyano,  $C_{1-4}$ alkyl, halo,  $-OR^{21}$ ,  $-NR^{21}R^{22}$ ,  $-CO_2R^{21}$  and  $-NR^{21}CO_2R^{22}$ .

7. A compound according to claim 6 wherein  $R^7$  is hydrogen or  $C_{1-4}$ alkyl optionally substituted with halo, hydroxy or  $C_{1-3}$ alkoxy.
8. A pharmaceutical composition comprising a compound according to claim 1 or claim 5 2; and a pharmaceutically-acceptable diluent or carrier.
9. A compound according to claim 1 or 2 for use as a medicament.
10. The use of a compound according to claim 1 or 2 in the manufacture of a medicament 10 in the treatment of a disease condition mediated  $TNF-\alpha$ .
11. The use of a compound according to claim 1 or 2 in the manufacture of a medicament in the treatment of autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm- 15 blooded animal such as man.
12. A method of treating autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal, such as man, in need of such treatment which comprises 20 administering to said animal an effective amount of a compound according to claim 1 or 2.
13. A process for preparing a compound according to claim 1 or 2, comprising the steps of converting a ketone or aldehyde of formula (2) into a compound of formula (1);



25

and thereafter if necessary:

- i) converting a compound of formula (1) into another compound of formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester